Billing News Apr 2020



SARS-CoV-2 Serology Testing Ramping Up to Address Next Stages of Pandemic

  • April 6, 2020

A number of academic and commercial labs are ramping up the development of serology tests for SARS-CoV-2, which could help manage the pandemic as it moves past its initial phases. Serology tests look for the presence of host antibodies against disease, which can indicate whether a person has been exposed to an infectious agent and potentially...

Read



Colorectal Cancer Shifting Toward Younger Adults

  • April 6, 2020

The new data, published online March 5, 2020, comes from the latest edition of Colorectal Cancer Statistics from the American Cancer Society. During the 2000s, the incidence of CRC has shown a rapid decline in individuals aged 65 and older, but has increased by 1% annually among those aged 50 to 64 years, and increased by 2%...

Read



Senate Bill Proposes Laboratory Developed Tests to Be Regulated under CLIA Process

  • April 6, 2020

On March 17, 2020, Sen. Rand Paul introduced S. 3512, the Verified Innovative Testing in American Laboratories (VITAL) Act of 2020. According to Sen. Paul, the VITAL Act would help diagnostic and prognostic tests become available more quickly during public health emergencies by securely placing laboratory-developed testing services solely under...

Read



UHC - Genetic and Molecular Prior Authorization Update

  • April 6, 2020

Effective May 1, 2020, for UnitedHealthcare Community Plan members in Virginia and Washington, and effective  June 1, 2020, for Ohio* members, we will require prior authorization and notification for genetic and molecular testing performed in an outpatient setting. Approval Will Be Required for the Following: • Tier 1 Molecular Pathology...

Read



New Specimen Collection Codes for Laboratories Billing for COVID-19 Testing

  • April 6, 2020

Clinical diagnostic laboratories: To identify and reimburse specimen collection for COVID-19 testing, CMS established two Level II HCPCS codes, effective with line item date of service on or after March 1, 2020: G2023 - Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any...

Read



ACLA Asks Congress For $5B to Meet SARS-CoV-2 Testing Demand

  • April 6, 2020

The American Clinical Laboratory Association on Thursday requested support from Congress for a $5 billion surge capacity fund to support the clinical lab industry in providing testing for SARS-CoV-2. Khani proposed the funds would cover costs related to uncompensated SARS-CoV-2 testing services for uninsured and under-insured patients; support...

Read



HIPAA Security Rule Update Related to COVID-19

  • April 6, 2020

On March 17, 2020, the federal Department of Health and Human Services (HHS) announced that the Office for Civil Rights (OCR) will suspend enforcement activities and waive penalties related to certain HIPAA Security Rule provisions “during the COVID-19 nationwide public health emergency.” Specifically, OCR will waive penalties for using...

Read



Commercial Labs Step up Coronavirus Test Efforts After FDA Guidance

  • April 6, 2020

LabCorp's test, called LabCorp 2019 Novel Coronavirus (COVID-19), NAA test, became available for ordering by physicians or other authorized healthcare providers in the US as of 6:00 PM ET. It will soon be joined by Quest Diagnostics, which said on Thursday that it plans to launch its SARS-CoV-2 test on March 9 to aid in the "presumptive...

Read